Transcriptomics

Dataset Information

0

Next Generation Sequencing of control (Untreated), PAN injured and Adriamycin injured human podocytes


ABSTRACT: Purpose: Next-generation sequencing (NGS) was used to identify cellular pathways and genes through systems-based analysis. The goals of this study are to identify NGS-derived transcriptome profiling (RNA-seq) in control (untreated) and Injured (PAN and Adriamycin) podocyte. These high throughput data were further validated through qRT–PCR methods to confirm the cellular pathways and genes affected due to the podocyte injury. Methods: Human podocytes were differentiated for 14 days by thermoswitching from 33⁰C to 37⁰C and removal of growth factors, insulin-transferrin-selenium from the medium.  These podocytes were incubated 4hour in serum free RPMI medium and injury was induced by using PAN (100μg/ml) and Adriamycin (0.25μg/ml) treatment for 48 hours.Further, podocytes were processed for RNA isolation and submitted to Medical University of South Carolina Sequencing Core facility for RNA-Seq. All the experiments were performed in triplicates. Conclusions: Our study is first to describe the detailed analysis of PAN and Adriamycin induced podocyte transcriptomes using the RNA-seq technology. A comparative analysis of the differential expression profile was obtained between control vs PAN injured podocytes, and control vs Adriamycin injured podocytes. Complex genetic network and genes effected due to the injury will provide a platform to define biological pathways participate during podocytes injury process.

ORGANISM(S): Homo sapiens

PROVIDER: GSE124622 | GEO | 2019/03/31

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2018-11-06 | GSE108629 | GEO
| PRJNA512858 | ENA
2024-03-20 | GSE262013 | GEO
2017-06-20 | GSE100185 | GEO
2022-06-22 | GSE206525 | GEO
2015-09-09 | E-GEOD-66107 | biostudies-arrayexpress
2021-02-19 | PXD022213 | Pride
| PRJNA439317 | ENA
2016-03-16 | E-GEOD-79291 | biostudies-arrayexpress
2020-07-29 | PXD012025 | Pride